Chinese Biotech GLP-1 Ecnoglutide Post-Lancet Publication Follow-Through: Xianweida's cAMP-Biased Agonist Continues Global-Launch Positioning
Following the August 22 Lancet Diabetes & Endocrinology publication of the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003, a first-in-class cAMP-biased GLP-1 receptor agonist that preferentially activates the cAMP signaling pathway over β-arrestin recruitment), Chinese biotech peptide activity continued through end of August into September. Ecnoglutide received its Chinese NMPA approval for type 2 diabetes January 30, 2026, followed by the March 6, 2026 approval for weight management in adults with overweight or obesity; the Lancet publication supplies the peer-reviewed data package supporting global regulatory submissions. Ecnoglutide is licensed to Pfizer under the up-to-$495 million partnership announced in 2024 for ex-China commercialization. The biased-agonism concept (selective signaling pathway activation to separate efficacy from tolerability) is now being pursued by CSPC (SYH2069 GLP-1/GIP dual-biased agonist) and other Chinese biotech peptide developers.